hotspot -WSS

hotspot

author：comprehensive 2025-09-29 18:18:27 - browse：8429

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Sanders adds drug shortage policies to pandemic preparedness bill

WSS

Testing GLP

Key House panel plots a new health care package

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Google and Epic fight stronger regulation of AI in health care

Readout Newsletter: Illumina, CRISPR, Regeneron

Diabetes management: Digital health tools fall short, study says

Wikipedia

hotspot

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Hepatitis C has a cure — but many Americans still lack access to it

Adam's Take: Intra

After affirmative action ruling, medical educators look to 'holistic review'

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

State Dept. review finds Biden bears some blame for Afghanistan failures

Diabetes management: Digital health tools fall short, study says

focus

Cosmetics set for new safety regulation. Why the industry is on board

Chinese researcher claims birth of first gene

Why hospitals are withdrawing from US News rankings

Yancopoulos of Regeneron works to expand Dupixent success

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

6 surprising facts about sugar

knowledge

explore

focus

focus